特发性肺纤维化预后生物标志物的研究进展
Research Progress of Prognostic Biomarkers in Idiopathic Pulmonary Fibrosis
DOI: 10.12677/ACM.2022.12101384, PDF,   
作者: 任 静, 于文成*：青岛大学附属医院呼吸与危重症医学科，山东 青岛
关键词: 特发性肺纤维化；生物标志物；预后；Idiopathic Pulmonary Fibrosis； Biomarkers； Prognosis
摘要: 特发性肺纤维化(IPF)是一种病因不明的慢性、进行性、纤维化性间质性肺疾病(ILD)，其特征是肺部结构和功能的不可逆性丧失，导致患者呼吸困难，呼吸衰竭和过早死亡。它是特发性间质肺炎最常见的类型，同时预后也最差。目前，已从IPF患者的血液、肺泡灌洗液、支气管肺组织等生物组织样本中发现多种有价值的生物标志物，尤其是通过血液中获得，因其具有易取样、创伤小、成本低、可连续重复监测等优点，具有较大的临床应用前景。本文从基因组学、血清蛋白质学和血液细胞学三个方面对近年来发现的与IPF预后相关的生物标志物进行综述，旨在为临床工作中IPF患者的管理选择合适的生物标志物提供参考，并在疾病早期更方便、快速地识别IPF预后不良的患者。
Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial lung disease (ILD) of unknown cause, characterized by irreversible loss of lung structure and function, resulting in dyspnea, respiratory failure, excessive lung function, and early death. It is the most common and the worst type of idiopathic interstitial pneumonia. At present, a variety of valuable biomarkers have been detected from biological samples such as blood, lavage fluid, and bronchopulmonary tis-sue of IPF patients. Especially from blood, because of its advantages of convenient acquisition, less trauma, low cost, and continuous monitoring, it has great prospects for clinical application. This ar-ticle reviews the biomarkers related to the prognosis of IPF discovered in recent years from three aspects: genomics, serum proteinology, and blood cytology. The purpose of this study is to provide a reference for clinical work to select appropriate biomarkers for the management of IPF patients, and to identify patients with poor prognosis of IPF at an early stage more conveniently and quickly.
文章引用：任静, 于文成. 特发性肺纤维化预后生物标志物的研究进展[J]. 临床医学进展, 2022, 12(10): 9569-9575. https://doi.org/10.12677/ACM.2022.12101384

参考文献

[1] Bonser, L.R. and Erle, D.J. (2017) Airway Mucus and Asthma: The Role of MUC5AC and MUC5B. Journal of Clinical Medicine, 6, Article No. 112. [Google Scholar] [CrossRef] [PubMed]
[2] Peljto, A.L., Zhang, Y., Fingerlin, T.E., Ma, S.-F., Garcia, J.G.N., Richards, T.J., Silveira, L.J., Lindell, K.O., Steele, M.P., Loyd, J.E., Gibson, K.F., Seibold, M.A., Brown, K.K., Talbert, J.L., Markin, C., Kossen, K., Seiwert, S.D., Murphy, E., Noth, I., Schwarz, M.I., Kaminski, N. and Schwartz, D.A. (2013) Association between the MUC5B Promoter Polymorphism and Survival in Patients with Id-iopathic Pulmonary Fibrosis. JAMA, 309, 2232-2239. [Google Scholar] [CrossRef] [PubMed]
[3] Seibold, M.A., Wise, A.L., Speer, M.C., Steele, M.P., Brown, K.K., Loyd, J.E., Fingerlin, T.E., Zhang, W., Gudmundsson, G., Groshong, S.D., Evans, C.M., Garantziotis, S., Adler, K.B., Dickey, B.F., du Bois, R.M., Yang, I.V., Herron, A., Kervitsky, D., Talbert, J.L., Markin, C., Park, J., Crews, A.L., Slifer, S.H., Auerbach, S., Roy, M.G., Lin, J., Hennessy, C.E., Schwarz, M.I. and Schwartz, D.A. (2011) A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis. The New England Journal of Medicine, 364, 1503-1512. [Google Scholar] [CrossRef] 
[4] Jiang, H., Hu, Y., Shang, L., Li, Y., Yang, L. and Chen, Y. (2015) Association between MUC5B Polymorphism and Susceptibility and Severity of Idiopathic Pulmonary Fibrosis. Interna-tional Journal of Clinical and Experimental Pathology, 8, 14953-14958.
[5] Samara, K.D., Antoniou, K.M., Karagian-nis, K., Margaritopoulos, G., Lasithiotaki, I., Koutala, E. and Siafakas, N.M. (2012) Expression Profiles of Toll-Like Receptors in Non-Small Cell Lung Cancer and Idiopathic Pulmonary Fibrosis. International Journal of Oncology, 40, 1397-1404. [Google Scholar] [CrossRef] [PubMed]
[6] O'Dwyer, D.N., Armstrong, M.E., Kooblall, M. and Don-nelly, S.C. (2015) Targeting Defective Toll-Like Receptor-3 Function and Idiopathic Pulmonary Fibrosis. Expert Opinion on Therapeutic Targets, 19, 507-514. [Google Scholar] [CrossRef] [PubMed]
[7] O'Dwyer, D.N., Armstrong, M.E., Trujillo, G., Cooke, G., Keane, M.P., Fallon, P.G., Simpson, A.J., Millar, A.B., McGrath, E.E., Whyte, M.K., Hirani, N., Hogaboam, C.M. and Donnelly, S.C. (2013) The Toll-Like Receptor 3 L412F Polymorphism and Disease Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 188, 1442-1450. [Google Scholar] [CrossRef] 
[8] McElroy, A.N., Invernizzi, R., Laskowska, J.W., O'Neill, A., Doroudian, M., Moghoofei, M., Mostafaei, S., Li, F., Przybylski, A.A., O'Dwyer, D.N., Bowie, A.G., Fallon, P.G., Maher, T.M., Hogaboam, C.M., Molyneaux, P.L., Hirani, N., Armstrong, M.E. and Donnelly, S.C. (2022) Candidate Role for Toll-Like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibro-sis. American Journal of Respiratory and Critical Care Medicine, 205, 550-562. [Google Scholar] [CrossRef] 
[9] Stewart, J.A., Chaiken, M.F., Wang, F. and Price, C.M. (2012) Maintaining the End: Roles of Telomere Proteins in End-Protection, Telomere Replication and Length Regulation. Muta-tion Research, 730, 12-19. [Google Scholar] [CrossRef] [PubMed]
[10] Borie, R., Tabèze, L., Thabut, G., Nunes, H., Cottin, V., Marchand-Adam, S., Prevot, G., Tazi, A., Cadranel, J., Mal, H., Wemeau-Stervinou, L., Bergeron Lafaurie, A., Isra-el-Biet, D., Picard, C., Reynaud Gaubert, M., Jouneau, S., Naccache, J.-M., Mankikian, J., Ménard, C., Cordier, J.-F., Valeyre, D., Reocreux, M., Grandchamp, B., Revy, P., Kannengiesser, C. and Crestani, B. (2016) Prevalence and Char-acteristics of TERT and TERC Mutations in Suspected Genetic Pulmonary Fibrosis. The European Respiratory Journal, 48, 1721-1731. [Google Scholar] [CrossRef] [PubMed]
[11] Alder, J.K., Chen, J.J.L., Lancaster, L., Danoff, S., Su, S.-c., Cogan, J.D., Vulto, I., Xie, M., Qi, X., Tuder, R.M., Phillips, J.A., Lansdorp, P.M., Loyd, J.E. and Ar-manios, M.Y. (2008) Short Telomeres Are a Risk Factor for Idiopathic Pulmonary Fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 105, 13051- 13056. [Google Scholar] [CrossRef] [PubMed]
[12] Armanios, M. (2013) Telomeres and Age-Related Disease: How Telomere Biology Informs Clinical Paradigms. The Journal of Clinical Investigation, 123, 996-1002. [Google Scholar] [CrossRef] 
[13] Dai, J., Cai, H., Zhuang, Y., Wu, Y., Min, H., Li, J., Shi, Y., Gao, Q. and Yi, L. (2015) Telomerase Gene Mutations and Telomere Length Shortening in Patients with Idiopathic Pulmonary Fibro-sis in a Chinese Population. Respirology (Carlton, Vic.), 20, 122-128. [Google Scholar] [CrossRef] [PubMed]
[14] Dai, J., Cai, H., Li, H., Zhuang, Y., Min, H., Wen, Y., Yang, J., Gao, Q., Shi, Y. and Yi, L. (2015) Association between Te-lomere Length and Survival in Patients with Idiopathic Pulmonary Fibrosis. Respirology (Carlton, Vic.), 20, 947-952. [Google Scholar] [CrossRef] [PubMed]
[15] Hisata, S., Kimura, Y., Shibata, N., Ono, S., Kobayashi, T., Chiba, S., Ohta, H., Nukiwa, T. and Ebina, M. (2011) A Normal Range of KL-6/MUC1 Independent of Elevated SP-D Indicates a Better Prognosis in the Patients with Honeycombing on High-Resolution Computed Tomography. Pulmonary Medicine, 2011, Article ID: 806014. [Google Scholar] [CrossRef] [PubMed]
[16] Satoh, H., Kurishima, K., Ishikawa, H. and Ohtsuka, M. (2006) In-creased Levels of KL-6 and Subsequent Mortality in Patients with Interstitial Lung Diseases. Journal of Internal Medi-cine, 260, 429-434. [Google Scholar] [CrossRef] [PubMed]
[17] Okamoto, T., Fujii, M., Furusawa, H., Tsuchiya, K., Miyazaki, Y. and Inase, N. (2015) The Usefulness of KL-6 and SP-D for the Diagnosis and Management of Chronic Hypersensitivity Pneumonitis. Respiratory Medicine, 109, 1576- 1581. [Google Scholar] [CrossRef] [PubMed]
[18] Xu, L., Bian, W., Gu, X.-H. and Shen, C. (2017) Differing Ex-pression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis. COPD, 14, 245-250. [Google Scholar] [CrossRef] [PubMed]
[19] Hamai, K., Iwamoto, H., Ishikawa, N., Horimasu, Y., Ma-suda, T., Miyamoto, S., Nakashima, T., Ohshimo, S., Fujitaka, K., Hamada, H., Hattori, N. and Kohno, N. (2016) Com-parative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fi-brosis. Disease Markers, 2016, Article ID: 4759040. [Google Scholar] [CrossRef] [PubMed]
[20] Yokoyama, A., Kondo, K., Nakajima, M., Matsushima, T., Takahashi, T., Nishimura, M., Bando, M., Sugiyama, Y., Totani, Y., Ishizaki, T., Ichiyasu, H., Suga, M., Hamada, H. and Kohno, N. (2006) Prognostic Value of Circulating KL-6 in Idiopathic Pulmonary Fibrosis. Respirology (Carlton, Vic.), 11, 164-168. [Google Scholar] [CrossRef] [PubMed]
[21] Sokai, A., Tanizawa, K., Handa, T., Kanatani, K., Kubo, T., Ikezoe, K., Nakatsuka, Y., Tokuda, S., Oga, T., Hirai, T., Nagai, S., Chin, K. and Mishima, M. (2017) Importance of Se-rial Changes in Biomarkers in Idiopathic Pulmonary Fibrosis. ERJ Open Research, 3, 1-8. [Google Scholar] [CrossRef] [PubMed]
[22] Wakamatsu, K., Nagata, N., Kumazoe, H., Oda, K., Ishimoto, H., Yoshimi, M., Takata, S., Hamada, M., Koreeda, Y., Takakura, K., Ishizu, M., Hara, M., Ise, S., Izumi, M., Akasaki, T., Maki, S., Kawabata, M., Mukae, H. and Kawasaki, M. (2017) Prognostic Value of Serial Serum KL-6 Measurements in Patients with Idiopathic Pulmonary Fibrosis. Respiratory Investigation, 55, 16-23. [Google Scholar] [CrossRef] [PubMed]
[23] Qiu, M., Chen, Y. and Ye, Q. (2018) Risk Factors for Acute Ex-acerbation of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. The Clinical Respiratory Journal, 12, 1084-1092. [Google Scholar] [CrossRef] [PubMed]
[24] Kohno, N., Awaya, Y., Oyama, T., Yamakido, M., Akiyama, M., Inoue, Y., Yokoyama, A., Hamada, H., Fujioka, S. and Hiwada, K. (1993) KL-6, a Mucin-Like Glycoprotein, in Bronchoalveolar Lavage Fluid from Patients with Interstitial Lung Disease. The American Review of Respiratory Disease, 148, 637-642. [Google Scholar] [CrossRef] [PubMed]
[25] Mulugeta, S., Nureki, S.-I. and Beers, M. F. (2015) Lost after Translation: Insights from Pulmonary Surfactant for Understanding the Role of Alveolar Epithelial Dysfunction and Cel-lular Quality Control in Fibrotic Lung Disease. American Journal of Physiology. Lung Cellular and Molecular Physiolo-gy, 309, L507-L525. [Google Scholar] [CrossRef] [PubMed]
[26] Greene, K.E., King, T.E., Kuroki, Y., Bucher-Bartelson, B., Hun-ninghake, G.W., Newman, L.S., Nagae, H. and Mason, R.J. (2002) Serum Surfactant Proteins-A and -D as Biomarkers in Idiopathic Pulmonary Fibrosis. The European Respiratory Journal, 19, 439-446. [Google Scholar] [CrossRef] [PubMed]
[27] Kinder, B.W., Brown, K.K., McCormack, F.X., Ix, J.H., Ker-vitsky, A., Schwarz, M.I. and King, T.E. (2009) Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis. Chest, 135, 1557-1563. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, K., Ju, Q., Cao, J., Tang, W. and Zhang, J. (2017) Impact of Se-rum SP-A and SP-D Levels on Comparison and Prognosis of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Medicine, 96, e7083. [Google Scholar] [CrossRef] 
[29] Nishikiori, H., Chiba, H., Ariki, S., Kuronuma, K., Otsuka, M., Shiratori, M., Ikeda, K., Watanabe, A., Kuroki, Y. and Takahashi, H. (2014) Distinct Compartmentalization of SP-A and SP-D in the Vasculature and Lungs of Patients with Idiopathic Pulmonary Fibrosis. BMC Pulmonary Medicine, 14, Article No. 196. [Google Scholar] [CrossRef] [PubMed]
[30] Maher, T.M., Oballa, E., Simpson, J.K., Porte, J., Habgood, A., Fahy, W.A., Flynn, A., Molyneaux, P.L., Braybrooke, R., Divyateja, H., Parfrey, H., Rassl, D., Russell, A.-M., Saini, G., Renzoni, E.A., Duggan, A.-M., Hubbard, R., Wells, A.U., Lukey, P.T., Marshall, R.P. and Jenkins, R.G. (2017) An Epithelial Biomarker Signature for Idiopathic Pulmonary Fibrosis: An Analysis from the Multicentre PROFILE Cohort Study. The Lancet Respiratory Medicine, 5, 946-955. [Google Scholar] [CrossRef] 
[31] Doubková, M., Karpíšek, M., Mazoch, J., Skřičková, J. and Doubek, M. (2016) Prognostic Significance of Surfactant Protein A, Surfactant Protein D, Clara Cell Protein 16, S100 Protein, Trefoil Factor 3, and Prostatic Secretory Protein 94 in Idiopathic Pulmonary Fibrosis, Sarcoidosis, and Chronic Pulmonary Obstructive Disease. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG, 33, 224-234.
[32] Morais, A., Beltrão, M., Sokhatska, O., Costa, D., Melo, N., Mota, P., Marques, A. and Delgado, L. (2015) Serum Metalloproteinases 1 and 7 in the Diagnosis of Idiopathic Pulmonary Fibrosis and Other Interstitial Pneu-monias. Respiratory Medicine, 109, 1063-1068. [Google Scholar] [CrossRef] [PubMed]
[33] Tzouvelekis, A., Herazo-Maya, J. D., Slade, M., Chu, J.-H., Deiuliis, G., Ryu, C., Li, Q., Sakamoto, K., Ibarra, G., Pan, H., Gulati, M., Antin-Ozerkis, D., Herzog, E.L. and Kaminski, N. (2017) Validation of the Prognostic Value of MMP-7 in Idiopathic Pulmonary Fibrosis. Respirology (Carlton, Vic.), 22, 486-493. [Google Scholar] [CrossRef] [PubMed]
[34] Richards, T.J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L.J., Lindell, K.O., Klesen, M., Zhang, Y. and Gibson, K.F. (2012) Peripheral Blood Proteins Predict Mortality in Idiopathic Pulmonary Fi-brosis. American Journal of Respiratory and Critical Care Medicine, 185, 67-76. [Google Scholar] [CrossRef] 
[35] Kreuter, M., Lee, J.S., Tzouvelekis, A., Oldham, J.M., Molyneaux, P.L., Weycker, D., Atwood, M., Kirchgaessler, K.U. and Maher, T.M. (2021) Monocyte Count as a Prog-nostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 204, 74-81. [Google Scholar] [CrossRef] 
[36] Nathan, S.D., Reffett, T., Brown, A.W., Fischer, C.P., Shlobin, O.A., Ahmad, S., Weir, N. and Sheridan, M.J. (2013) The Red Cell Distribution width as a Prognostic Indicator in Idio-pathic Pulmonary Fibrosis. Chest, 143, 1692-1698. [Google Scholar] [CrossRef] [PubMed]
[37] Chen, Y., Cai, J., Zhang, M. and Yan, X. (2022) Prognostic Role of NLR, PLR and MHR in Patients with Idiopathic Pulmonary Fibrosis. Frontiers in Immunology, 13, Article ID: 882217. [Google Scholar] [CrossRef] [PubMed]
[38] Zinellu, A., Paliogiannis, P., Sotgiu, E., Mellino, S., Mangoni, A.A., Zinellu, E., Negri, S., Collu, C., Pintus, G., Serra, A., Pistuddi, A.M., Carru, C., Pirina, P. and Fois, A.G. (2020) Blood Cell Count Derived Inflammation Indexes in Patients with Idiopathic Pulmonary Fibrosis. Lung, 198, 821-827. [Google Scholar] [CrossRef] [PubMed]
[39] Nathan, S.D., Mehta, J., Stauffer, J., Morgenthien, E., Yang, M., Limb, S.L. and Bhorade, S. (2021) Changes in Neutrophil-Lymphocyte or Platelet-Lymphocyte Ratios and Their Associ-ations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 10, Article No. 1427. [Google Scholar] [CrossRef] [PubMed]
[40] Ruta, V.M., Man, A.M., Alexescu, T.G., Motoc, N.S., Tarmure, S., Ungur, R.A., Todea, D.A., Coste, S.C., Valean, D. and Pop, M.C. (2020) Neutrophil-to-Lymphocyte Ratio and Systemic Immune-Inflammation Index-Biomarkers in Interstitial Lung Disease. Medicina (Kaunas), 56, Article No. 381. [Google Scholar] [CrossRef] [PubMed]

为你推荐